<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05044637</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE: 50193921.6.1001.0005</org_study_id>
    <nct_id>NCT05044637</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Primaquine for Radical Cure of Uncomplicated Plasmodium Vivax Malaria in Children</brief_title>
  <acronym>CHILDPRIM</acronym>
  <official_title>Phase IIB Study to Evaluate Primaquine Safety and Tolerability for Radical Cure of Uncomplicated Plasmodium Vivax Malaria in Children &lt; 15 Years-old (CHILDPRIM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundação de Medicina Tropical Dr. Heitor Vieira Dourado</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundação de Medicina Tropical Dr. Heitor Vieira Dourado</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main determinant of primaquine efficacy is the total dose of primaquine administered,&#xD;
      rather than the dosing schedule. Infants and children younger than 4 years of age are at a&#xD;
      higher risk of frequent relapses than older age groups, which may lead to severe anaemia. In&#xD;
      view of this issue, after Glucose-6-phosphate dehydrogenase (G6PD) testing, WHO recommends&#xD;
      the use of a low dose (0·25 mg/kg of bodyweight) of primaquine for 14 days in infants aged 6&#xD;
      months and older, as a follow-up treatment for malaria caused by P. vivax and P. ovale.&#xD;
      Nevertheless, previous trials have demonstrated that the standard low dose regimen of&#xD;
      primaquine (3.5 mg/kg total) fails to prevent relapses in many different endemic locations.&#xD;
      For this reason, the 2010 WHO antimalarial guidelines now recommend a high dose regimen of 7&#xD;
      mg/kg (equivalent to an adult dose of 30mg per day), although many countries still recommend&#xD;
      lower doses for fear of causing more serious harm to unscreened G6PD deficiency patients.&#xD;
&#xD;
      The pharmacokinetics of several antimalarial drugs are different in children younger than 10&#xD;
      years of age or who are underweight for their age compared with children of 10 years and&#xD;
      older and adults.The doses of several antimalarials in children are suboptimal. This&#xD;
      oversight is a consequence of designing dosing regimens in a different population (i.e.,&#xD;
      adults) for the one most affected by the disease and this has led to revisions of some dosing&#xD;
      recommendations. The different pharmacokinetic performance of drugs in children might also&#xD;
      relate to maturation (e.g., of metabolic processes, particularly in the first 2 years of&#xD;
      life). Pharmacogenomic factors affecting drug metabolism are increasingly being studied.&#xD;
      Polymorphisms in cytochrome P4502D6 are associated with different primaquine metabolizer&#xD;
      phenotypes with resulting differing efficacies for radical cure. Shorter courses of higher&#xD;
      daily doses of primaquine have the potential to improve adherence and, thus, effectiveness&#xD;
      without compromising efficacy. If the efficacy, tolerability and safety of short-course,&#xD;
      high-dose primaquine regimens can be assured across the range of endemic settings, along with&#xD;
      reliable point-of-care G6PD deficiency diagnostics, then this would be a major advance in&#xD;
      malaria treatment by improving adherence and thus the effectiveness of anti-relapse therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Adverse Event</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>To diagnose, resolve and catalog adverse events of any intensity, whether clinical or laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy - Radical cure</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>The incidence rate (i.e., per person-year) of symptomatic recurrent P. vivax parasitaemia (detected by microscopy) over 6 months of follow-up in the 3.5 mg/Kg total dose versus 7.0 mg/Kg total dose primaquine groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence rate (per person-year) of recurrent P. vivax</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>The overall incidence rate (per person-year) of any recurrent P. vivax parasitaemia detected by microscopy over 6 months of follow-up in the 3.5 mg/Kg total dose group versus the 7.0 mg/Kg total dose groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence risk of any recurrent symptomatic P. vivax malaria</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>The incidence rate (per person-year) of any recurrent symptomatic P. vivax parasitaemia over 6 months of follow-up in either the 7-day or the 14-day primaquine arms of 7.0 mg/kg total dose compared with 7-day primaquine arm of 3.5 mg/Kg total dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The hematological recovery in patients with vivax malaria</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>Hematological recovery will be assessed as the incidence risk of severe anaemia (Hb&lt;7g/dl) and/or blood transfusion within the 6 month follow up period, and the mean fall in baseline Hb on day 7 and day 14. These outcomes will be compared between the treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with any adverse drug reactions</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>The proportion of patients with one or more adverse drug reactions within 42 days of their primary treatment and also at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primaquine tolerability 1 hour</measure>
    <time_frame>7 to 14 days after randomization</time_frame>
    <description>Tolerability of primaquine will be assessed by comparing the proportion of patients with nausea, vomiting, abdominal pain and vomiting of a dose within 1 hour of administration between the treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primaquine tolerability</measure>
    <time_frame>7 to 14 days after randomization</time_frame>
    <description>Drug tolerability between the treatment arms will also be assessed by comparing the proportion of patients completing a full course of primaquine therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenetics CYP2D6</measure>
    <time_frame>1 day after randomization</time_frame>
    <description>Characterize hepatic cytochrome CYP2D6 enzyme phenotypes using Activity Score A (AS-A)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotype CYP2D6</measure>
    <time_frame>1 day after randomization</time_frame>
    <description>Genotype CYP2D6 alleles in this study population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomics</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>Describe the metabolic signatures present in patients with adverse events (AEs) and severe AEs (SAEs)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory - Pharmacokinetics of primaquine Area Under the Curve (AUC)</measure>
    <time_frame>24 hours</time_frame>
    <description>Area under the plasma concentration time AUC 0-∞curve for primaquine and metabolites (mPQ)</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory - Pharmacokinetics of primaquine Conc</measure>
    <time_frame>24 hours</time_frame>
    <description>Primaquine and metabolites maximum concentrations</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory - Pharmacokinetics of primaquine Elimination rate</measure>
    <time_frame>24 hours</time_frame>
    <description>Primaquine and metabolites (mPQ) elimination rate constants (mPQ-λz)</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory - Pharmacokinetics of primaquine Elimination half-life</measure>
    <time_frame>24 hours</time_frame>
    <description>Primaquine and metabolites (mPQ) elimination half- life (mPQ-t1/2)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">445</enrollment>
  <condition>Malaria, Vivax</condition>
  <arm_group>
    <arm_group_label>Primaquine (3.5mg x 7d)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Primaquine 7 days Standard blood schizontocidal therapy plus 7 days of unsupervised primaquine (3.5 mg/kg total dose) administered once per day (0.5 mg/kg OD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primaquine (7.0mg x 7d)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Primaquine 7 days Standard blood schizontocidal therapy plus 7 days of unsupervised primaquine (7.0 mg/kg total dose) administered once per day (1.0 mg/kg OD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primaquine (7.0mg x 14d)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Primaquine 14 days Standard blood schizontocidal therapy plus 14 days of unsupervised primaquine (7.0 mg/kg total dose) administered once per day (0.5 mg/kg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primaquine</intervention_name>
    <description>7 days of unsupervised primaquine (3.5 mg/kg total dose) administered once per day (0.5 mg/kg OD).</description>
    <arm_group_label>Primaquine (3.5mg x 7d)</arm_group_label>
    <other_name>Low-standard dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primaquine</intervention_name>
    <description>7 days of supervised primaquine (7.0 mg/kg total dose) administered once per day (1.0 mg/kg OD).</description>
    <arm_group_label>Primaquine (7.0mg x 7d)</arm_group_label>
    <other_name>High-dose short course</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primaquine</intervention_name>
    <description>14 days of unsupervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).</description>
    <arm_group_label>Primaquine (7.0mg x 14d)</arm_group_label>
    <other_name>High-dose long course</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infection with P.vivax parasitaemia;&#xD;
&#xD;
          -  ≥ 6 months and ˂ 15 years of age;&#xD;
&#xD;
          -  Body weight ≥ 5 Kg;&#xD;
&#xD;
          -  Hb &gt; 7 g/dL&#xD;
&#xD;
          -  presence of axillary temperature &gt;37.5 Celsius or history of fever during the past 48&#xD;
             hours;&#xD;
&#xD;
          -  ability to swallow oral medication;&#xD;
&#xD;
          -  Abscence of severe malnutrition (defined as a child whose growth standard is below&#xD;
             -3-Z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm&#xD;
             circumference &lt; 110 mm)&#xD;
&#xD;
          -  Abscence of febrile conditions due to disease other than malaria (e.g., measles, acute&#xD;
             lower respiratory tract infection, severe diarrhea with dehydration) or the known&#xD;
             underlying chronic or severe diseases (e.g., cardiac, renal, hepatic diseases,&#xD;
             HIV/AIDS);&#xD;
&#xD;
          -  History of hypersensitivity reactions to or contraindicated for any of the medicine(s)&#xD;
             being teste d or used as alternative treatment(s);&#xD;
&#xD;
          -  A negative pregnancy test or non-lactating&#xD;
&#xD;
          -  Ability and willingness to comply with the study protocol for the duration of the&#xD;
             study, including 6 months of follow up;&#xD;
&#xD;
          -  Informed consent from the patient/parent/guardian.&#xD;
&#xD;
          -  Informed assent in addition to parental consent of any participant between 7 and 14&#xD;
             years of age;&#xD;
&#xD;
          -  Pregnancy test consent from girls of childbearing age (defined as having had menarche)&#xD;
             and their parents or guardians;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  G6PD- Deficiency (&lt; 4.0 U/g Hb)&#xD;
&#xD;
          -  The subject has severe P. vivax malaria as defined by the World Health Organization&#xD;
             (WHO) criteria&#xD;
&#xD;
          -  intolerance of or allergy to one of the medications in the study&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Inability to tolerate oral medication&#xD;
&#xD;
          -  Blood tranfusion in the last 3 months (as this may mask the G6PD deficiency)&#xD;
&#xD;
          -  Serious or chronic medical condition (cardiac, renal, hepatic diseases, sickle cell&#xD;
             disease, HIV/AIDS)&#xD;
&#xD;
          -  History of malaria in the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria das Graças C Alecrim, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundação de Medicina Tropical - HVD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcus Vinicius G Lacerda, PhD, MD</last_name>
    <phone>+559221273498</phone>
    <email>marcuslacerda.br@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universidade Federal do Acre</name>
      <address>
        <city>Cruzeiro Do Sul</city>
        <state>Acre</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suaine CN do Vale, PhD, MD</last_name>
      <email>suianec39@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundação de Medicina Tropical Doutor Heitor Vieira Dourado</name>
      <address>
        <city>Manaus</city>
        <state>Amazonas</state>
        <zip>69040-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wuelton M Monteiro, PhD</last_name>
      <phone>+55 (92) 2127 3498</phone>
      <email>wueltonmm@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Vivax</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primaquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

